Phocas Financial Corp. Decreases Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Phocas Financial Corp. trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 85.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,699 shares of the company’s stock after selling 32,190 shares during the period. Phocas Financial Corp.’s holdings in Mirum Pharmaceuticals were worth $236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Frazier Life Sciences Management L.P. raised its holdings in Mirum Pharmaceuticals by 1.2% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock valued at $256,245,000 after buying an additional 75,000 shares during the period. State Street Corp raised its holdings in Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after buying an additional 297,511 shares during the period. Geode Capital Management LLC raised its holdings in Mirum Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after buying an additional 29,017 shares during the period. Lord Abbett & CO. LLC purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $28,913,000. Finally, Loomis Sayles & Co. L P purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $19,473,000.

Insider Activity

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the transaction, the chief executive officer now owns 119,359 shares in the company, valued at $5,110,952.38. The trade was a 5.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $85,554.36. Following the completion of the transaction, the chief operating officer now owns 27,015 shares in the company, valued at $1,156,782.30. This trade represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,915 shares of company stock worth $1,897,920. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $50.52 on Thursday. The firm has a market cap of $2.43 billion, a P/E ratio of -25.01 and a beta of 0.96. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23. The stock’s fifty day moving average price is $46.72 and its 200-day moving average price is $43.32.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Citigroup increased their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $57.10.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.